Role of ABCB1 C1236T, G2677T, and C3435T genetic polymorphisms in the development of acute leukemia in a Chinese population

Abstract

ABSTRACT. We carried out a case-control study to examine the relationship between the ATP-binding cassette subfamily B member 1 (ABCB1) gene polymorphisms C1236T, G2677T, and C3435T and risk of acute leukemia in a Chinese population. Between May 2013 and April 2015, we recruited 164 acute leukemia patients and 285 healthy controls, and determined polymorphism genotypes by polymerase chain reactionrestriction fragment length polymorphism. Using unconditional logistic regression analysis, we observed that in comparison to the wild-type sequence, the TT genotype [odds ratio (OR) = 2.15, 95% confidence interval (CI) = 1.12-4.10; P = 0.01] and the T allele (OR = 1.39, 95%CI = 1.05-1.86; P = 0.02) of ABCB1 G2677T were associated with acute leukemia susceptibility. The TT genotype (OR = 2.03, 95%CI = 1.11-3.69; P = 0.01) and the T allele (OR = 1.39, 95%CI = 1.05-1.85; P = 0.02) of the C3435T polymorphism also increased acute leukemia risk compared to the wild-type form. However, no significant relationship was established between the ABCB1 C1236T variant and this disease. Our results suggest that the ABCB1 G2677T and C3435T sequence variations may affect susceptibility to acute leukemia.

A study of the association of C3435T polymorphism of MDR1 gene and its mRNA expression with the level of daunorubicin accumulation in leukocytes in patients with chronic myeloproliferative diseases

“…Среди веществ, транспортируемых из цитоплазмы в межклеточную жидкость Pgp-переносчиком, описаны фармакологические средства терапии хронического миелолейкоза (ХМЛ) и Ph-негативных миелопролиферативных новообразований (ХМН) [1]. Показано также, что слабый полиморфизм C3435T гена MDR1 ассоциирован с более высоким риском развития онкогематологических заболеваний: острых лейкозов [2] и ХМЛ [3,4]. В различных этнических группах было продемонстрировано влияние полиморфизмов MDR1 на развитие резистентности к терапии ХМЛ иматинибом [3][4][5][6][7][8][9].…”